Beyond making medicines – the role of Pharma | Lutz Hegemann, President Novartis Global Health

With more than half of the people on the African continent not having access to basic essential medicines according to the World Health Organization resulting in an estimated one million deaths, the challenge of poor access to medicines will not be solved by one government or a single organization alone. There is only so much that any single organization can do and that is why partnership is so important. Pharma cannot simply reduce its contribution to the provision of medicines but need to care about the benefits to society at large. Pharmaceutical companies are a key partner in solving the challenge of access to reach more people so that innovations are not just sitting on the shelf. Beyond making medicines, society expects pharma companies to have a clear access agenda so that it is innovating for the many not only the few. The private sector need to make sure that innovation reaches patients. It need to go beyond the transactional approach and take a keen interest in how medicines are being used in order to deliver the greatest value to society. We need medicines that are fit-for-purpose in resource contrained settings to allow us to better utilize those solutions when resources are limited. There are challenges with deploying innovation in the best interest of patients which leads patients be diagnosed in the community way too late when they may no longer quality for disease modifying therapy thereby worsening health outcomes. So we need to find areas in the health systems where we can work together in order to reduce those barriers. It the past it has taken 10 years for innovation to reach African patients after it was available in Europe on the US. It is possible to eliminate this gap to a zero time gap as was recently done with a product that was approved by the Food and Drugs Authority,Ghana and the Swiss regulator Swissmedic within the same time frame. We need an ecosystem that makes it possible for African innovation to be more visible and to thrive. There are some exceptionally bright people who can drive innovation in Africa for Africa and for the world. The sickle cell gene therapy that Novartis is working on in collaboration with the Bill and Melinda Gates Foundation is one example of that. I am optimistic that over the next decade we will see things like this happening.